OneStep ELISA Kit for 1,5-Anhydroglucitol (1,5-AG) 
LycoMark; 1-Deoxy-D-glucose; 1-Deoxy-D-glucopyranose; 1,5-Anhydro-D-glucitol; 1,5-Anhydrosorbitol; Aceritol; Polygalytol
Overview
Properties
- Product No.OEB046Ge
- Organism SpeciesPan-species (General) Same name, Different species.
- ApplicationsEnzyme-linked immunosorbent assay for Antigen Detection.
Research use only - DownloadInstruction Manual
- Category
Sign into your account
Share a new citation as an author
Upload your experimental result
Review
Contact us
Please fill in the blank.
-
Packages (Simulation)
-
Packages (Simulation)
-
ISO9001: 2008, ISO13485: 2003 Registered
Recovery
Matrices listed below were spiked with certain level of 1,5-Anhydroglucitol (1,5-AG) and the recovery rates were calculated by comparing the measured value to the expected amount of 1,5-Anhydroglucitol (1,5-AG) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 83-105 | 95 |
| EDTA plasma(n=5) | 87-97 | 93 |
| heparin plasma(n=5) | 99-105 | 102 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level 1,5-Anhydroglucitol (1,5-AG) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level 1,5-Anhydroglucitol (1,5-AG) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of 1,5-Anhydroglucitol (1,5-AG) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 85-99% | 80-99% | 93-102% | 98-105% |
| EDTA plasma(n=5) | 88-96% | 91-105% | 82-95% | 87-95% |
| heparin plasma(n=5) | 97-105% | 90-98% | 95-102% | 96-105% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
Assay procedure summary
1. Prepare all reagents, samples and standards;
2. Add 50µL standard or sample to each well, then add 50µL prepared Detection Reagent A to each well. Incubate 1 hour at 37°C;
3. Aspirate and wash 3 times;
4. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
5. Add 50µL Stop Solution. Read at 450nm immediately.
Test principle
This assay employs the competitive inhibition enzyme immunoassay technique. An antibody specific to 1,5-Anhydroglucitol (1,5-AG) has been pre-coated onto a microplate. A competitive inhibition reaction is launched between HRP labeled 1,5-Anhydroglucitol (1,5-AG) and unlabeled 1,5-Anhydroglucitol (1,5-AG) (Standards or samples) with the pre-coated antibody specific to 1,5-Anhydroglucitol (1,5-AG). After incubation, the unbound conjugate is washed off. The amount of bound HRP conjugate is reverse proportional to the concentration of 1,5-Anhydroglucitol (1,5-AG) in the sample. After addition of the substrate solution, the intensity of color developed is reverse proportional to the concentration of 1,5-Anhydroglucitol (1,5-AG) in the sample.
Giveaways
Increment services
Citations
- A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK-and HNF1A-MODY than in type 2 diabetes mellituspubmed:28593615
- Salivary 1, 5-Anhydroglucitol and Vitamin Levels in Relation to Caries Risk in Children
- Continuous subcutaneous insulin infusion combined with liraglutide reduced glycemic variability and oxidative stress in type 2 diabetes mellitus: a study based on the …Pubmed: 31243192
- Modulation of gut microbiota contributes to effects of intensive insulin therapy on intestinal morphological alteration in high-fat-diet-treated micePubmed: 31749050